Form 4: Provectus Biopharmaceuticals Director Edward Pershing Reports Conversion of Convertible Note into Preferred Stock

Director Edward Pershing reports the conversion of a convertible promissory note into Series D-1 Convertible Preferred Stock of Provectus Biopharmaceuticals.

Summary

• On February 27, 2024, Edward Pershing, a director of Provectus Biopharmaceuticals, reported the conversion of an 8% unsecured convertible promissory note into 37,744 shares of Series D-1 Convertible Preferred Stock.
• The conversion occurred at a price of $2.862 per share.
• The Series D-1 Convertible Preferred Stock is convertible into common stock at a rate of 10 shares of common stock per share of preferred stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into common stock on June 20, 2026, unless earlier converted.
• Following the transaction, Pershing beneficially owns 1,046,572 shares of common stock and $1,435,000 of Series D-1 Convertible Preferred Stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to a conversion of securities. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about an insider transaction.

Future Outlook

The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

Industry Context

This filing is a routine disclosure related to insider transactions and provides transparency regarding the holdings of a company director. It doesn't necessarily reflect broader industry trends but is important for investors monitoring insider activity.

Stakeholder Impact

• The conversion of the note into preferred stock could potentially dilute existing shareholders if the preferred stock is later converted into common stock.

Key Dates